Fate Therapeutics公司近日成功入选美国食品药品监督管理局（FDA）的化学、制造与控制开发与准备试点计划。该计划旨在支持其创新疗法FT819的生产准备工作，标志着公司在细胞疗法制造领域的重要进展。
Fate Therapeutics公司近日成功入选美国食品药品监督管理局（FDA）的化学、制造与控制开发与准备试点计划。该计划旨在支持其创新疗法FT819的生产准备工作，标志着公司在细胞疗法制造领域的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.